Publications

Oral bemnifosbuvir (AT-527) vs placebo in patients with mild-to-moderate COVID-19 in an outpatient setting (MORNINGSKY)

Source

A. Horga, R. Saenz, G. Yilmaz, A. Simón-Campos, K. Pietropaolo, W. Stubbings, N. Collinson, L. Ishak, B. Zrinscak, B. Belanger, C. Granier, K. Lin, A. Hurt, X. Zhou, S. Wildum & J. Hammond. Published Online: 1 Nov 2023. doi.org/10.2217/fvl-2023-0115

Bemnifosbuvir and ruzasvir are potent HCV DAAs with favorable antiviral profiles against major HCV NS5A and NS5B RAVs supporting use in combination

Source

American Association for the Study of Liver Diseases’ (AASLD), The Liver Meeting 2023

Lack of pharmacokinetic drug–drug interaction between bemnifosbuvir and ruzasvir in healthy participants

Source

American Association for the Study of Liver Diseases’ (AASLD), The Liver Meeting 2023

Bemnifosbuvir (AT-527) Treatment of Non-Hospitalized Individuals with Mild to Moderate COVID-19: Results from a Truncated Phase 3, Randomized, Double-Blind, Placebo-Controlled Trial (MORNINGSKY)

Source

33rd European Congress of Clinical Microbiology & Infectious Diseases (ECCMID 2023)

AT-752, A Novel Nucleotide Prodrug With Pan-Serotype Activity Against Dengue Virus, Does Not Affect Cardiac Repolarization: Results From a Robust QT/QTc Evaluation in Healthy Participants

Source

33rd European Congress of Clinical Microbiology & Infectious Diseases (ECCMID 2023)